Javascript must be enabled to continue!
Challenges in Development of Nanomedicine for Treatment of Cancer
View through CrossRef
The inherent limitations of conventional cancer therapies have stimulated the growth of cancer nanomedicine. This is primarily attributable to its unique features for drug delivery, diagnosis and imaging, synthetic vaccine development and miniature medical devices, supplemented with the inherent therapeutic property of some nanomaterials. Nanotherapies that integrate some of these features are already in use and others have great potential in clinical development, with definitive results in near future. In order to develop smart cancer nanomedicine, it is very essential to bridge the gap between Bio-Nanoscience and Cancer Nanomedicine with a better understanding about the molecular basis of cancer. The development of smart cancer nanomedicine can be accelerated by patient stratification, rational drug selection, combination therapy, synergism with immunotherapeutics. The nanoplatforms that exhibit a significant increase in progression free survival are most desirable.
Title: Challenges in Development of Nanomedicine for Treatment of Cancer
Description:
The inherent limitations of conventional cancer therapies have stimulated the growth of cancer nanomedicine.
This is primarily attributable to its unique features for drug delivery, diagnosis and imaging, synthetic vaccine development and miniature medical devices, supplemented with the inherent therapeutic property of some nanomaterials.
Nanotherapies that integrate some of these features are already in use and others have great potential in clinical development, with definitive results in near future.
In order to develop smart cancer nanomedicine, it is very essential to bridge the gap between Bio-Nanoscience and Cancer Nanomedicine with a better understanding about the molecular basis of cancer.
The development of smart cancer nanomedicine can be accelerated by patient stratification, rational drug selection, combination therapy, synergism with immunotherapeutics.
The nanoplatforms that exhibit a significant increase in progression free survival are most desirable.
Related Results
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract
Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...
Abstract 1856: Adaptation to dopamine impairs the anti-cancer effect of ONC201 and ONC206
Abstract 1856: Adaptation to dopamine impairs the anti-cancer effect of ONC201 and ONC206
Abstract
ONC201 (originally discovered as TRAIL-Inducing Compound #10 or TIC10) and analogue ONC206 have been found to induce an integrated stress response with sugg...
11 Years of CLINAM, the European Foundation for Clinical Nanomedicine
11 Years of CLINAM, the European Foundation for Clinical Nanomedicine
CLINAM is a nonprofit organization based in Basel, Switzerland (www.clinam.org), that has been founded by Beat Löffler and Patrick Hunziker in 2007. The organization, utilizing its...
Comprehensive update on cancer scenario of Bangladesh
Comprehensive update on cancer scenario of Bangladesh
AbstractBangladesh, at 142 million people, is the ninth most populous country in the world. There are 13 to 15 lakh cancer patients in Bangladesh, with about two lakh patients newl...

